TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adolescent Vaccination in the Medical Home: Established and Innovative Strategies
Brief Summary: In this project, the investigators will develop, implement, and evaluate an adolescent vaccination quality improvement program, with the program designed to encourage adolescents to visit their usual primary care provider to receive vaccinations and other recommended preventive health services. This study will be conducted in different types of primary care settings, such as public, private, and managed care clinics serving adolescent patients of diverse backgrounds, and will provide important information to help guide future public health efforts to achieve high rates of immunization in adolescents.


Options:
A: Arm Label: Reminder/Recall Strategy; Type: EXPERIMENTAL; Interventions: Behavioral: Text Message Reminder/Recall, Behavioral: Parent Preference | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text Message Reminder/Recall; Assigned to Arm(s): Reminder/Recall Strategy | Intervention Type: BEHAVIORAL; Name: Parent Preference; Assigned to Arm(s): Reminder/Recall Strategy
B: Arm Label: Telephone reminder; Type: EXPERIMENTAL; Interventions: Other: Telephone reminder | Arm Label: Text Message reminder; Type: EXPERIMENTAL; Interventions: Other: Text Message reminder | Arm Label: Control: Telephone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control: Text Message; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telephone reminder; Assigned to Arm(s): Telephone reminder | Intervention Type: OTHER; Name: Text Message reminder; Assigned to Arm(s): Text Message reminder
C: Arm Label: General Adolescent Vaccine Brochure; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General Adolescent Vaccine Brochure | Arm Label: HPV brochure, recall, reminders; Type: EXPERIMENTAL; Interventions: Behavioral: HPV brochure, recall, reminders | Intervention Type: BEHAVIORAL; Name: HPV brochure, recall, reminders; Assigned to Arm(s): HPV brochure, recall, reminders | Intervention Type: BEHAVIORAL; Name: General Adolescent Vaccine Brochure; Assigned to Arm(s): General Adolescent Vaccine Brochure
D: Arm Label: Collaborative Population-Based Recall-Phone/Mail Group; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Pop-Based R/R: Phone/Mail Group | Arm Label: Collaborative Population-Based Recall-Mail Only Group; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Pop-Based R/R: Mail-Only Group | Arm Label: Practice-based Recall; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Practice-based Recall | Intervention Type: BEHAVIORAL; Name: Collaborative Pop-Based R/R: Phone/Mail Group; Assigned to Arm(s): Collaborative Population-Based Recall-Phone/Mail Group | Intervention Type: BEHAVIORAL; Name: Collaborative Pop-Based R/R: Mail-Only Group; Assigned to Arm(s): Collaborative Population-Based Recall-Mail Only Group | Intervention Type: BEHAVIORAL; Name: Practice-based Recall; Assigned to Arm(s): Practice-based Recall

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stress Management Among Latinos With Type 2 Diabetes Mellitus
Brief Summary: The primary aims of this study are to:

1. Tailor a diabetes stress management intervention for delivery by community health workers (CHWs) serving an urban Latino population.
2. Investigate the efficacy of the stress management intervention on glycemic control.

   Secondary aims of this study are to:
3. Investigate the efficacy of the stress management intervention on stress hormones, psychosocial functioning, and stress-glucose reactivity.

Study hypothesis:

A CHW-led group-based diabetes education model enhanced with stress management education will improve glycemic control more than CHW-led group-based diabetes education alone.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Procedure: Web-based care management | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Telephone and face-to-face care management | Arm Label: Arm 3; Type: SHAM_COMPARATOR; Interventions: Procedure: Internet access alone | Intervention Type: PROCEDURE; Name: Web-based care management; Assigned to Arm(s): Arm 1 | Intervention Type: PROCEDURE; Name: Telephone and face-to-face care management; Assigned to Arm(s): Arm 2 | Intervention Type: PROCEDURE; Name: Internet access alone; Assigned to Arm(s): Arm 3
B: Arm Label: Diabetes education; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Diabetes education plus stress management; Type: EXPERIMENTAL; Interventions: Behavioral: stress management | Intervention Type: BEHAVIORAL; Name: stress management; Assigned to Arm(s): Diabetes education plus stress management
C: Arm Label: Reciprocal Diabetes Peer Support program; Type: EXPERIMENTAL; Interventions: Behavioral: Reciprocal Diabetes Peer Support Program, Behavioral: group outpatient counseling visits | Arm Label: Nurse Case Management; Type: OTHER; Interventions: Behavioral: Nurse Case management | Intervention Type: BEHAVIORAL; Name: Reciprocal Diabetes Peer Support Program; Assigned to Arm(s): Reciprocal Diabetes Peer Support program | Intervention Type: BEHAVIORAL; Name: Nurse Case management; Assigned to Arm(s): Nurse Case Management | Intervention Type: BEHAVIORAL; Name: group outpatient counseling visits; Assigned to Arm(s): Reciprocal Diabetes Peer Support program
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Dialogue to Educate and Activate (IDEA) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual Education (IE) | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interactive Dialogue to Educate and Activate (IDEA); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Individual Education (IE); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Brief Summary: This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in participants with metastasized or locally advanced, inoperable, somatostatin receptor positive, histologically proven midgut carcinoid tumours with progression despite LAR treatment.


Options:
A: Arm Label: Lanreotide Autogel (Somatuline Depot) 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Lanreotide | Arm Label: Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lanreotide; Assigned to Arm(s): Lanreotide Autogel (Somatuline Depot) 120 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE
B: Arm Label: lanreotide (Autogel formulation); Type: EXPERIMENTAL; Interventions: Drug: lanreotide (Autogel formulation) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lanreotide (Autogel formulation); Assigned to Arm(s): lanreotide (Autogel formulation) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 177Lu-DOTA0-Tyr3-Octreotate; Type: EXPERIMENTAL; Interventions: Drug: Octreotide LAR, Drug: 177Lu-DOTA0-Tyr3-Octreotate | Arm Label: Octreotide LAR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide LAR | Intervention Type: DRUG; Name: Octreotide LAR; Assigned to Arm(s): 177Lu-DOTA0-Tyr3-Octreotate, Octreotide LAR | Intervention Type: DRUG; Name: 177Lu-DOTA0-Tyr3-Octreotate; Assigned to Arm(s): 177Lu-DOTA0-Tyr3-Octreotate
D: Arm Label: Everolimus 10 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus 10 mg/day | Intervention Type: DRUG; Name: Everolimus Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pelvic Floor Muscle Training Included in General Fitness Classes is Effective in Primary Prevention of Urinary Incontince in Pregnancy. A Randomized Controlled Trial
Brief Summary: To investigate the effect of pelvic floor muscle training taught in a general exercise class during pregnancy to prevent urinary incontinence in nulliparous continent pregnant women.


Options:
A: Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Other: Exercise classes with pelvic floor muscle training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise classes with pelvic floor muscle training; Assigned to Arm(s): Exercise group
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: A supervised physical exercise program | Intervention Type: BEHAVIORAL; Name: A supervised physical exercise program; Assigned to Arm(s): Exercise group
C: Arm Label: iball intervention; Type: EXPERIMENTAL; Interventions: Device: iball (mhealth application) | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: iball (mhealth application); Assigned to Arm(s): iball intervention
D: Intervention Type: BEHAVIORAL; Name: Supervised exercise for the prevention high weight gain; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pelvic Floor Muscle Training Included in General Fitness Classes is Effective in Primary Prevention of Urinary Incontince in Pregnancy. A Randomized Controlled Trial
Brief Summary: To investigate the effect of pelvic floor muscle training taught in a general exercise class during pregnancy to prevent urinary incontinence in nulliparous continent pregnant women.


Options:
A: Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Other: Exercise classes with pelvic floor muscle training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise classes with pelvic floor muscle training; Assigned to Arm(s): Exercise group
B: Arm Label: Combination therapy; Type: EXPERIMENTAL; Interventions: Drug: Tolterodine, Behavioral: Behavioral training | Arm Label: Drug therapy alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine | Intervention Type: DRUG; Name: Tolterodine; Assigned to Arm(s): Combination therapy, Drug therapy alone | Intervention Type: BEHAVIORAL; Name: Behavioral training; Assigned to Arm(s): Combination therapy
C: Arm Label: Behavioral Treatment alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral training | Arm Label: Drug Therapy (Tolterodine + tamsulosin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine + tamsulosin | Arm Label: Combined Behavioral + Drug Therapy; Type: EXPERIMENTAL; Interventions: Other: Combined Behavioral + Drug Therapy | Intervention Type: BEHAVIORAL; Name: Behavioral training; Assigned to Arm(s): Behavioral Treatment alone | Intervention Type: DRUG; Name: Tolterodine + tamsulosin; Assigned to Arm(s): Drug Therapy (Tolterodine + tamsulosin) | Intervention Type: OTHER; Name: Combined Behavioral + Drug Therapy; Assigned to Arm(s): Combined Behavioral + Drug Therapy
D: Arm Label: Postpartum pelvic floor muscle training; Type: EXPERIMENTAL; Interventions: Other: Postpartum pelvic floor muscle training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Postpartum pelvic floor muscle training; Assigned to Arm(s): Postpartum pelvic floor muscle training

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pelvic Floor Muscle Training Included in General Fitness Classes is Effective in Primary Prevention of Urinary Incontince in Pregnancy. A Randomized Controlled Trial
Brief Summary: To investigate the effect of pelvic floor muscle training taught in a general exercise class during pregnancy to prevent urinary incontinence in nulliparous continent pregnant women.


Options:
A: Arm Label: exercise; Type: EXPERIMENTAL; Interventions: Behavioral: specific training program | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: standard | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): control | Intervention Type: BEHAVIORAL; Name: specific training program; Assigned to Arm(s): exercise
B: Arm Label: Physical & Behavioral Therapy Group; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Therapy (PT) and Behavioral Therapy (BT) | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Therapy (PT) and Behavioral Therapy (BT); Assigned to Arm(s): Physical & Behavioral Therapy Group
C: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Educational Workshop | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational Workshop; Assigned to Arm(s): Intervention
D: Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Other: Exercise classes with pelvic floor muscle training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise classes with pelvic floor muscle training; Assigned to Arm(s): Exercise group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Brief Summary: The purpose of this study is to determine objective response rate (ORR), lasting at least 4 months (ORR4), with brentuximab vedotin in participants with cluster of differentiation antigen 30 positive (CD30+) cutaneous T-cell lymphoma \[mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) \]compared to that achieved with therapy in the control arm.


Options:
A: Arm Label: Brentuximab vedotin; Type: EXPERIMENTAL; Interventions: Drug: Brentuximab Vedotin | Arm Label: Methotrexate or Bexarotene; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Bexarotene | Intervention Type: DRUG; Name: Brentuximab Vedotin; Assigned to Arm(s): Brentuximab vedotin | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate or Bexarotene | Intervention Type: DRUG; Name: Bexarotene; Assigned to Arm(s): Methotrexate or Bexarotene
B: Arm Label: Bexarotene and PUVA; Type: EXPERIMENTAL; Interventions: Drug: bexarotene, Drug: methoxypsoralen, Procedure: UV light therapy | Arm Label: PUVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: methoxypsoralen, Procedure: UV light therapy | Intervention Type: DRUG; Name: bexarotene; Assigned to Arm(s): Bexarotene and PUVA | Intervention Type: DRUG; Name: methoxypsoralen; Assigned to Arm(s): Bexarotene and PUVA, PUVA | Intervention Type: PROCEDURE; Name: UV light therapy; Assigned to Arm(s): Bexarotene and PUVA, PUVA
C: Arm Label: 1 (PG - NM (MCH) 0.02%); Type: ACTIVE_COMPARATOR; Interventions: Drug: mechlorethamine-MCH (nitrogen mustard) | Arm Label: 2 (AP - MCH(NM) 0.02%); Type: ACTIVE_COMPARATOR; Interventions: Drug: mechlorethamine-MCH (nitrogen mustard) | Intervention Type: DRUG; Name: mechlorethamine-MCH (nitrogen mustard); Assigned to Arm(s): 1 (PG - NM (MCH) 0.02%), 2 (AP - MCH(NM) 0.02%)
D: Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Medication Safety of Elderly Patients in Hospital and Ambulatory Setting Considering the Transitions of Care for Home-cared Patients and Nursing Home Residents
Brief Summary: The purpose of this study is to determine whether additional pharmaceutical care for elderly patients (home-cared patients, nursing-home residents) has a positive impact on drug-related readmissions.


Options:
A: Arm Label: Patient Navigator; Type: EXPERIMENTAL; Interventions: Other: Patient Navigator, Other: Usual care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient Navigator; Assigned to Arm(s): Patient Navigator | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Patient Navigator
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: Drug review 80+ -To reduce usage of hospital care | Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Drug review 80+ -To reduce usage of hospital care; Assigned to Arm(s): I
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pharmacist intervention; Type: EXPERIMENTAL; Interventions: Behavioral: multidisciplinary treatment | Intervention Type: BEHAVIORAL; Name: multidisciplinary treatment; Assigned to Arm(s): Pharmacist intervention
D: Arm Label: standard care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intensified standard care; Type: OTHER; Interventions: Other: Pharmaceutical Care Service | Intervention Type: OTHER; Name: Pharmaceutical Care Service; Assigned to Arm(s): Intensified standard care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Randomized Placebo-controlled Trial to Evaluate the Efficacy of the ELTGOL Technique in the Drainage of Secretions in Patients With Bronchiectasis
Brief Summary: The ELTGOL technique improves mucociliary clearance in adult patients with bronchiectasis.

Primary objective:

-To evaluate the efficacy of ELTGOL in stable state patients with bronchiectasis compared to placebo.

Secondary objectives:

* To evaluate the level of knowledge of airway clearance techniques and adherence to them in patients with bronchiectasis.
* To assess the side effects during the procedure: oxygen desaturation, increased dyspnea and hemoptysis.


Options:
A: Arm Label: Airway clearance, bronchiectasis; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Low Expiration Open glottis inferolateral (ELTGOL) | Arm Label: bronchiectasis, stretching; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Stretching | Intervention Type: PROCEDURE; Name: Low Expiration Open glottis inferolateral (ELTGOL); Assigned to Arm(s): Airway clearance, bronchiectasis | Intervention Type: PROCEDURE; Name: Stretching; Assigned to Arm(s): bronchiectasis, stretching
B: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
C: Arm Label: Observational; Type: N/A; Interventions: N/A
D: Arm Label: Acapella Physiotherapy; Type: EXPERIMENTAL; Interventions: Device: Acapella Physiotherapy | Arm Label: No physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Acapella Physiotherapy; Assigned to Arm(s): Acapella Physiotherapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Brief Summary: The purpose of the study is to evaluate whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression free survival (PFS) as compared to treatment with ofatumumab in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)


Options:
A: Arm Label: Lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: lenalidomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): Lenalidomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ofatumumab (Arm A); Type: ACTIVE_COMPARATOR; Interventions: Drug: ofatumumab | Arm Label: ibrutinib (Arm B); Type: EXPERIMENTAL; Interventions: Drug: ibrutinib | Intervention Type: DRUG; Name: ofatumumab; Assigned to Arm(s): Ofatumumab (Arm A) | Intervention Type: DRUG; Name: ibrutinib; Assigned to Arm(s): ibrutinib (Arm B)
C: Arm Label: Bendamustine + GA101 + CAL-101; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: GA101, Drug: CAL-101 | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + GA101 + CAL-101 | Intervention Type: DRUG; Name: GA101; Assigned to Arm(s): Bendamustine + GA101 + CAL-101 | Intervention Type: DRUG; Name: CAL-101; Assigned to Arm(s): Bendamustine + GA101 + CAL-101
D: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Salpingectomy During Laparoscopic Hysterectomy on Ovarian Function
Brief Summary: The purpose of this study is to assess the feasibility of performing a randomized clinical trial evaluating the effect of salpingectomy (removal of the fallopian tubes) during laparoscopic hysterectomy on ovarian function. The hypothesis is that removal of the tubes can prevent diseases of the fallopian tubes such as infection, hydrosalpinx (fluid-filled tubes)and additional invasive procedures such as further imaging work-ups and further surgery related to the tubes.


Options:
A: Arm Label: Salpingectomy with delayed oophorectomy; Type: EXPERIMENTAL; Interventions: Procedure: Salpingectomy with delayed oophorectomy | Arm Label: Risk-reducing salpingo-oophorectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Risk-reducing salpingo-oophorectomy | Intervention Type: PROCEDURE; Name: Salpingectomy with delayed oophorectomy; Assigned to Arm(s): Salpingectomy with delayed oophorectomy | Intervention Type: PROCEDURE; Name: Risk-reducing salpingo-oophorectomy; Assigned to Arm(s): Risk-reducing salpingo-oophorectomy
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Device: Eclipse™ System | Intervention Type: DEVICE; Name: Eclipse™ System; Assigned to Arm(s): Treatment
C: Arm Label: Salpingectomy group; Type: EXPERIMENTAL; Interventions: Procedure: Salpingectomy | Arm Label: No Salpingectomy Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Salpingectomy; Assigned to Arm(s): Salpingectomy group
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Iltamiocel; Type: EXPERIMENTAL; Interventions: Biological: Iltamiocel | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Iltamiocel; Assigned to Arm(s): Iltamiocel

Answer: C